Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JYNNEOS is a suspension for subcutaneous injection (0.5 mL) based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.
Lead Product(s): Live Nonreplicating Smallpox And Monkeypox Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bavarian Nordic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 19, 2022
Details:
The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate.
Lead Product(s): Ad26.COV2-S
Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 25, 2020